Prostate cancer is the most common malignancy encountered in corrections. While screening guidelines are well standardized, therapy options have become increasingly more complicated. Active surveillance remains a reasonable therapy option while robotic surgery can be considered the default therapy of choice in terms of cost and long-term complications. Advances in radiation therapy have expanded treatment options and can reduce the number of off-site transports. The role of new therapeutics, including hormonal options and novel radiopharmaceuticals, will be discussed, along with their effect on physicians' treatment decisions and patient outcomes.

Educational Objectives

• Identify patients appropriate for PSA screening
• Review treatment options for patients with low, intermediate, and high-risk prostate cancer
• Discuss hypofractionated radiation therapy

Level: 

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC